• For Institutions

    • Corporate Services
    • Developers
  • Download
  • Help
  • About

    • Company Profile
    • License & Regulatory
    • Media coverage
longbridgelongbridge
longbridgelongbridge
Products
Pricing
Markets
Global Markets
Stock Screener
Information
Insights
News
Live
Academy
Affiliate Program
Promotions
PortAI
EN
English
简体中文
繁體中文
繁體中文(廣東話)Posts & comments will be shown in Cantonese
Search...
Quote ListQuote List
Overview
News
Financials
© 2025 Longbridge|Disclaimer

Event Tracking

Dec6
Arvinas Announces Support for ARV-393 and Glofitamab Combination Therapy for DLBCL and Plans Phase 1 Clinical Trial
13:05
Nov24
Arvinas Inc. to Present Multiple Abstracts on Vepdegestrant at San Antonio Breast Cancer Symposium
12:00
Nov5
TD Cowen Analyst Maintains Hold Rating on Arvinas Holding
18:27
Arvinas released FY2025 Q3 earnings on November 5, Pre-Market (EST), actual revenue USD 41.9 M (forecast USD 27.55 M), actual EPS USD -0.4795 (forecast USD -0.7166)
14:30
Arvinas released FY2025 9 Months earnings on November 5 Pre-Market (EST), actual revenue USD 253.1 M, actual EPS USD -0.1795
14:30
Arvinas Reports Q3 2025 Earnings
12:07

Schedules & Filings

Schedules
Filings
Nov5
Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 41.9 M, Net Income -35.1 M, EPS -0.4795

Aug6
Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 22.4 M, Net Income -61.2 M, EPS -0.84

May1
Earning Release(EST)

FY2025 Q1 Earning Release (USD) Revenue 188.8 M, Net Income 82.9 M, EPS 1.14

View More

Stock List

Top Gainers
Top Decliners
China Concepts
Symbol
Price
%Chg
Change
PCLA
0.3600
+192.45%
+0.237
STEC
1.530
+59.38%
+0.570
HIHO
1.250
+50.60%
+0.420
TRIB
1.280
+43.50%
+0.388
EUDA
1.920
+41.18%
+0.560
AFJK
44.010
+37.49%
+12.000
SOC
10.360
+36.32%
+2.760
POM
0.3499
+30.95%
+0.083
ASTI
5.060
+30.41%
+1.180
ASPC
16.100
+29.42%
+3.660
View More